GLP-1 & Metabolic
Vive GLP(R)
Formula
- Size
- 6mg
Specifications
Vive GLP(R) Technical Profile
OVERVIEW
What Is Retatrutide Peptide?
Retatrutide (also known by its research designation LY3437943) is a synthetic 39-amino acid peptide that functions as a triple agonist, simultaneously activating the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This retatrutide triple agonist profile makes it the first peptide of its class to engage all three of these metabolically relevant receptor systems, positioning it as a groundbreaking tool in metabolic research.
As a retatrutide peptide for research, the compound builds on the dual-agonist approach of tirzepatide by adding glucagon receptor activity. The inclusion of glucagon receptor agonism introduces an additional dimension of metabolic signaling, glucagon is known to influence hepatic glucose output, lipid oxidation, and energy expenditure in preclinical models. Retatrutide research represents the cutting edge of multi-receptor agonist peptide biology, and buying retatrutide online from a trusted USA supplier like VivePeptides ensures researchers access the highest quality compound available.
- 01
Triple Receptor Agonist
First-in-class peptide targeting GIP, GLP-1, and glucagon receptors simultaneously
- 02
≥99% HPLC Purity
Every batch verified via high-performance liquid chromatography
- 03
USA Tested & Verified
Third-party analytical testing performed in USA laboratories
RESEARCH
Retatrutide Mechanism of Action in Research
The retatrutide mechanism of action is uniquely complex, involving simultaneous engagement of three G-protein coupled receptors that regulate distinct but interconnected metabolic pathways. Retatrutide research has begun to elucidate how triple receptor agonism may produce effects distinct from single or dual agonist approaches.
GIP and GLP-1 Receptor Co-Agonism
Like tirzepatide, retatrutide activates both GIP and GLP-1 receptors. Research indicates that dual incretin receptor activation triggers complementary intracellular signaling cascades, including cAMP-mediated pathways in pancreatic beta cells, enteroendocrine cells, and central nervous system neurons. Published data suggest retatrutide demonstrates meaningful agonist activity at both receptors, contributing to its multifaceted research profile (Coskun et al., Cell Metabolism, 2022).
Glucagon Receptor Agonism
The defining feature of retatrutide research is its glucagon receptor agonist activity. Glucagon receptor activation in hepatocytes has been shown to stimulate glycogenolysis, gluconeogenesis, and lipid oxidation pathways in preclinical models. Studies suggest that the addition of glucagon receptor agonism may influence energy expenditure and hepatic lipid metabolism in ways not achievable through GIP/GLP-1 agonism alone, making retatrutide a unique research tool.
Integrated Metabolic Signaling
Emerging retatrutide research explores how the three receptor signals integrate at the cellular and systemic level. The interplay between incretin-mediated insulin signaling and glucagon-mediated counter-regulatory responses creates a complex pharmacological landscape that researchers are actively investigating in multiple preclinical model systems. ---
COMPARISON
Retatrutide vs Semaglutide: Research Peptide Comparison
Retatrutide
Comparing retatrutide and semaglutide illustrates the evolution from selective single-receptor agonism to multi-receptor strategies in metabolic peptide research.
Semaglutide
Researchers studying the contribution of glucagon receptor signaling to metabolic regulation may prefer retatrutide for sale from VivePeptides, while those requiring a well-characterized single-receptor agonist may choose semaglutide. Both are available at retatrutide 99% purity and semaglutide 99% purity from our USA-based facility.
| Feature | Retatrutide | Semaglutide |
|---|---|---|
| Receptor Targets | GIP + GLP-1 + Glucagon (triple agonist) | GLP-1 (selective agonist) |
| CAS Number | 2381089-83-2 | 910463-68-2 |
| Molecular Weight | ~4803.75 Da | 4113.58 Da |
| Amino Acids | 39 | 31 |
| Receptor Count | 3 | 1 |
| Glucagon Activity | Yes | No |
| GIP Activity | Yes | No |
| Research Stage | Emerging compound with growing literature | Extensively published, well-characterized |
RESEARCH STUDIES
Retatrutide Research Applications & Published Studies
Retatrutide research is a rapidly expanding field, with foundational studies establishing its pharmacological profile and in vivo characteristics in animal models.
Triple Agonist Characterization
The foundational retatrutide research publication by Coskun et al. (Cell Metabolism, 2022) characterized retatrutide's activity at all three target receptors using in vitro binding and signaling assays. This study established the receptor potency profile and demonstrated that retatrutide produces dose-dependent activation of GIP, GLP-1, and glucagon receptor-mediated signaling pathways.
Metabolic Research in Animal Models
Published retatrutide research in rodent and non-human primate models has documented effects on body weight, food intake, glucose tolerance, and energy expenditure parameters. Studies indicate that triple receptor agonism may produce distinct metabolic effects compared to dual or single agonist compounds, though the relative contribution of each receptor pathway remains an active area of investigation.
Hepatic Lipid Metabolism
Emerging retatrutide research has highlighted its effects on hepatic lipid metabolism in animal models, potentially related to its glucagon receptor agonist activity. Published data suggest that glucagon receptor activation may promote hepatic fatty acid oxidation and reduce lipid accumulation, providing a mechanistic rationale for the unique profile of triple agonist peptides.
QUALITY ASSURANCE
Quality & Testing Standards
HPLC & Mass Spectrometry
Every retatrutide batch is analyzed by HPLC and mass spectrometry to verify identity, purity, and molecular weight accuracy.
Third-Party Verified
All retatrutide is independently tested at third-party USA-based analytical laboratories. Testing documentation available for each lot.
≥99% Purity Standard
VivePeptides retatrutide consistently meets or exceeds ≥99% purity for dependable research outcomes.
FAQ
Frequently Asked Questions About Retatrutide
What is retatrutide used for in research?
What purity is VivePeptides retatrutide?
How should retatrutide be stored?
What distinguishes retatrutide from dual agonists like tirzepatide?
Is VivePeptides retatrutide third-party tested?
Add To Research Cart
Vive GLP(R)
99%+ purity · USA lab tested · secure shipping
